Clinical pharmacist involved in treatment of a patient with hepatitis B virus and advanced lung adenocarcinoma

Yuanna CHEN,Xiaofen YE,Yutong GU,Yingyun CAI,Qianzhou LV
DOI: https://doi.org/10.3969/j.issn.1006-1533.2016.23.023
2016-01-01
Abstract:A 62-year-old man was hospitalized due to cough and sputum for more than 2 years and chest pain 10 days. According to the pathological results of bronchoscopic biopsy, right lung adenocarcinoma was clearly diagnosed. The clinician intended to give the patient chemotherapy of PP regimen (pemetrexed disodium 0.8 g d1+cisplatin 130 mg d1). The pharmacist, considering the patient was a HBV carrier and chemotherapy may lead to HBV reactivation, recommended to give anti-HBV therapy during the whole chemotherapy by consulting literature. According to the characteristics of anti-HBV drugs, entecavir was preferred. The clinician adopted this suggestion and prescribed entecavir (0.5 mg, po, qd). Finally, the patient successfully completed chemotherapy and was discharged.
What problem does this paper attempt to address?